

CITATION REPORT

List of articles citing

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

DOI: 10.1111/dom.12932

Diabetes, Obesity and Metabolism, 2017, 19, 1242-1251.

Source: <https://exaly.com/paper-pdf/66058338/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
196	Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1242-1251	6.7	137
195	Obesity Pharmacotherapy in Patients With Type 2 Diabetes. 2017 , 30, 250-257		17
194	Semaglutide-the "" in the field of glucagon-like peptide-1 receptor agonists?. <i>Annals of Translational Medicine</i> , 2017 , 5, 475	3.2	7
193	Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. <i>Current Obesity Reports</i> , 2018 , 7, 147-161	8.4	116
192	Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment. 2018 , 58, 1314-1323		41
191	Incretins: Beyond type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20 Suppl 1, 59-67	6.7	6
190	Homeostatic and non-homeostatic appetite control along the spectrum of physical activity levels: An updated perspective. 2018 , 192, 23-29		47
189	Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 610-619	6.7	69
188	G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus. 2018 , 70, 39-67		53
187	Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 378-388	6.7	48
186	Food cravings and body weight: a conditioning response. 2018 , 25, 298-302		13
185	Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes. <i>Endocrine Reviews</i> , 2018 , 39, 719-738	27.2	75
184	No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects. 2018 , 9, 1441-1456		6
183	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2210-2219	6.7	44
182	The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis. 2018 , 142, 222-235		12
181	Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. 2018 , 52, 1224-1232		3
180	Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys. 2018 , 159, 3105-3119		15

179	No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century. <i>Frontiers in Endocrinology</i> , 2018 , 9, 442	5.7	12
178	Food Intake and Eating Behavior After Bariatric Surgery. 2018 , 98, 1113-1141		72
177	Changes in food reward during weight management interventions - a systematic review. 2018 , 19, 1642-1658		21
176	The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. 2018 , 62, 535-545		9
175	Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. 2018 , 392, 637-649		242
174	Anti-Obesity Therapy: from Rainbow Pills to Polyagonists. 2018 , 70, 712-746		82
173	The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs. 2018 , 20, S233-S241		14
172	Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. 2018 , 57, 1529-1538		13
171	Treatment: New Drugs. 2019 , 464-472		
170	A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 120-128	6.7	84
169	Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients. 2019 , 13, 2489-2494		10
168	Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series. 2019 , 11, 219-224		14
167	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. 2019 , 45, 409-418		54
166	Treatment strategies against diabetes: Success so far and challenges ahead. 2019 , 862, 172625		53
165	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. 2019 , 7, 834-844		81
164	Appetite Control Biological and Psychological Factors. 2019 , 17-22		2
163	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. 2019 , 62, 665-675		51
162	Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. 2019 , 42, 1446-1453		47

161	Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity. <i>Current Obesity Reports</i> , 2019 , 8, 284-291	8.4	14
160	Pharmaceutical approaches to weight management: behavioural mechanisms of action. 2019 , 12, 26-32		1
159	Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives. 2019 , 14, 421-431		8
158	Population Pharmacokinetics of Semaglutide for Type 2 Diabetes. 2019 , 10, 649-662		6
157	Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy. 2019 , 13, 731-738		14
156	Quantifying Appetite and Satiety. 2019 , 121-140		
155	Is reducing appetite beneficial for body weight management in the context of overweight and obesity? A systematic review and meta-analysis from clinical trials assessing body weight management after exposure to satiety enhancing and/or hunger reducing products. 2019 , 20, 983-997		11
154	The Discovery and Development of Liraglutide and Semaglutide. <i>Frontiers in Endocrinology</i> , 2019 , 10, 155	5.7	181
153	Semaglutide as a promising antiobesity drug. 2019 , 20, 805-815		33
152	Application of -Dodecyl l-Peptide to Enhance Serum Stability while Maintaining Inhibitory Effects on Myometrial Contractions Ex Vivo. 2019 , 24,		2
151	Effect of Sequence of Fruit Intake in a Meal on Satiety. 2019 , 16,		0
150	New advances and novel approaches in obesity pharmacotherapy. 2019 , 4, 75-82		1
149	Pharmacotherapy of obesity: Available medications and drugs under investigation. 2019 , 92, 170-192		98
148	Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review. <i>Endocrine Reviews</i> , 2019 , 40, 193-235	27.2	41
147	Metabolic dynamics of human Sertoli cells are differentially modulated by physiological and pharmacological concentrations of GLP-1. 2019 , 362, 1-8		12
146	Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial. 2020 , 44, 353-361		12
145	Measuring food preference and reward: Application and cross-cultural adaptation of the Leeds Food Preference Questionnaire in human experimental research. 2020 , 80, 103824		21
144	Intestinal Hormones. 2020 , 361-381		

143	An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. 2020 , 21, 275-285		16
142	Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. 2020 , 116, 916-930		33
141	Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors. 2020 , 180, 114150		8
140	Glucagon-like peptide-1, a matter of taste?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 1	10.5	4
139	Validation of the Activity Preference Assessment: a tool for quantifying children's implicit preferences for sedentary and physical activities. 2020 , 17, 108		5
138	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. 2020 , 8,		11
137	Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient. 2020 , 7, 332-339		
136	Weight-centric pharmacological management of type 2 diabetes mellitus - An essential component of cardiovascular disease prevention. 2020 , 34, 107619		7
135	The obesity epidemic in the face of homeostatic body weight regulation: What went wrong and how can it be fixed?. 2020 , 222, 112959		10
134	The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications. <i>Current Obesity Reports</i> , 2020 , 9, 136-149	8.4	9
133	Semaglutide injection for the treatment of adults with type 2 diabetes. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 675-684	3.8	3
132	A Role for GLP-1 in Treating Hyperphagia and Obesity. 2020 , 161,		25
131	What Should I Eat and Why? The Environmental, Genetic, and Behavioral Determinants of Food Choice: Summary from a Pennington Scientific Symposium. 2020 , 28, 1386-1396		2
130	Champ4life Study Protocol: A One-Year Randomized Controlled Trial of a Lifestyle Intervention for Inactive Former Elite Athletes with Overweight/Obesity. <i>Nutrients</i> , 2020 , 12,	6.7	7
129	Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach. 2021 , 34, 7-19		2
128	Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial. 2021 , 38, 550-561		3
127	GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. <i>Molecular Metabolism</i> , 2021 , 46, 101102	8.8	108
126	The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 754-762	6.7	29

125	Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 581-588	6.7	13
124	Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23 Suppl 1, 50-62	6.7	14
123	Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?. 2021 , 15, 59-68		3
122	Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. <i>Nutrients</i> , 2021 , 13,	6.7	6
121	Pharmacologie de l'obésité vers de nouvelles options. 2021 , 663-672		
120	Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?. 2021 , 11, e12439		8
119	Food-based concepts used for appetite manipulation in humans [A systematic review of systematic reviews with meta-analyses. 2021 , 22, 100322		0
118	Safety and efficacy of an extended-release peptide YY analogue for obesity: A randomized, placebo-controlled, phase 1 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1471-1483	6.7	2
117	GLP-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans. <i>Molecular Metabolism</i> , 2021 , 45, 101163	8.8	4
116	Once-Weekly Semaglutide in Adults with Overweight or Obesity. 2021 , 384, 989		351
115	The Role of the Gut Microbiota in the Gut-Brain Axis in Obesity: Mechanisms and Future Implications. 2021 , 22,		6
114	Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity-Therapeutic Implications. <i>Nutrients</i> , 2021 , 13,	6.7	5
113	Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. <i>Molecular Metabolism</i> , 2021 , 46, 101090	8.8	40
112	Emerging synthetic drugs for the treatment of liver cirrhosis. 2021 , 26, 149-163		5
111	Future directions in obesity pharmacotherapy. 2021 , 93, 13-20		6
110	Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. 2021 , 38, 2821-2839		10
109	Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. 2021 , 397, 1736-1748		55
108	A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. 2021 , 81, 1003-1030		7

107	Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. <i>Frontiers in Endocrinology</i> , 2021 , 12, 645507	5.7	5
106	MECHANISMS IN ENDOCRINOLOGY: Human brown adipose tissue as a therapeutic target: warming up or cooling down?. 2021 , 184, R243-R259		3
105	Obesity and GLP-1. 2021 , 46, 168-176		4
104	Evaluation of a child food reward task and its association with maternal feeding practices. 2021 , 16, e0254773		
103	How glucagon-like peptide 1 receptor agonists work. 2021 , 10, R200-R212		4
102	Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2344-2353	6.7	1
101	Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial. 2021 , 22, 464		1
100	Patient initiation and maintenance of GLP-1 RAs for treatment of obesity. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 1193-1204	3.8	5
99	GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. <i>Frontiers in Endocrinology</i> , 2021 , 12, 721135	5.7	7
98	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. 2021 , 31, 3257-3270		4
97	Diets and drugs for weight loss and health in obesity - An update. 2021 , 140, 111789		11
96	Mechanisms of weight loss after obesity surgery. <i>Endocrine Reviews</i> , 2021 ,	27.2	5
95	Oral semaglutide in the management of type 2 DM: Clinical status and comparative analysis. <i>Current Drug Targets</i> , 2021 ,	3	
94	GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH. <i>Frontiers in Endocrinology</i> , 2021 , 12, 721198	5.7	0
93	Evaluation of the impact of gastric bypass surgery on eating behaviour using objective methodologies under residential conditions: Rationale and study protocol. <i>Contemporary Clinical Trials Communications</i> , 2021 , 24, 100846	1.8	0
92	Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 94-105	6.7	2
91	Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021 ,	6.7	
90	Natural products in the management of obesity: Fundamental mechanisms and pharmacotherapy. <i>South African Journal of Botany</i> , 2021 , 143, 176-197	2.9	1

89	Application in medicine: obesity and satiety control. 2021 , 629-664		
88	Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. <i>Current Obesity Reports</i> , 2021 , 10, 14-30	8.4	31
87	G protein-coupled receptors: structure- and function-based drug discovery. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 7	21	44
86	Semaglutide lowers body weight in rodents via distributed neural pathways. <i>JCI Insight</i> , 2020 , 5,	9.9	94
85	A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. <i>Endocrinology and Metabolism</i> , 2019 , 34, 247-262	3.5	22
84	GLP-1 physiology informs the pharmacotherapy of obesity. <i>Molecular Metabolism</i> , 2021 , 57, 101351	8.8	9
83	Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. <i>Endocrine Reviews</i> , 2021 ,	27.2	4
82	THE RELATIONSHIP BETWEEN PHYSICAL ACTIVITY, OVERWEIGHTNESS AND OBESITY IN ADULTS. <i>Journal of Kinesiology and Exercise Sciences</i> , 2017 , 27, 87-94	0.1	
81	SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide. <i>Annals of Translational Medicine</i> , 2018 , 6, 129	3.2	
80	Clinical potential of treatment with semaglutide in type 2 diabetes patients. <i>Drugs in Context</i> , 2019 , 8, 212585	5.2	2
79	Factors associated with quality of life and weight regain 12 years after Roux-en-Y gastric bypass. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021 , 1	5.2	1
78	Wegovy (semaglutide): a new weight loss drug for chronic weight management. <i>Journal of Investigative Medicine</i> , 2021 ,	2.9	8
77	Drug Pipeline for Obesity Therapy. 2020 , 921-934		
76	SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence. <i>Journal of Diabetes Research</i> , 2021 , 2021, 9032378	3.9	0
75	Assessing the Continuation of Glucagon-Like Peptide-1 Receptor Agonists When Weight and HBA1C Are Not Reduced. <i>Metabolic Syndrome and Related Disorders</i> , 2020 , 18, 321-327	2.6	
74	Research Progress of Liraglutide in Improving Obesity. <i>Advances in Clinical Medicine</i> , 2021 , 11, 5501-5506		
73	Food Reward after a Traditional Inuit or a Westernised Diet in an Inuit Population in Greenland.. <i>Nutrients</i> , 2022 , 14,	6.7	0
72	SEMAGLUTIDE FOR WEIGHT LOSS. <i>Cardiology in Review</i> , 2022 , Publish Ahead of Print,	3.2	0

71	Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients.. <i>Metabolites</i> , 2022 , 12,	5.6	0
70	Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.. <i>Journal of Investigative Medicine</i> , 2022 , 70, 3-4	2.9	2
69	An integrated platform approach enables discovery of potent, selective and ligand-competitive cyclic peptides targeting the GIP receptor.. <i>Chemical Science</i> , 2022 , 13, 3256-3262	9.4	2
68	[New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus tablets), an oral GLP-1 receptor agonist].. <i>Folia Pharmacologica Japonica</i> , 2022 , 157, 146-154	0	
67	The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?. <i>Journal of Obesity and Metabolic Syndrome</i> , 2022 ,	4.4	1
66	Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 ,	6.1	1
65	Adjunctive Therapy, Including Pharmacotherapy. 2022 , 279-296		
64	Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists.. <i>Journal of Diabetes Research</i> , 2022 , 2022, 4554996	3.9	1
63	NSAID-Induced Enteropathy Affects Regulation of Hepatic Glucose Production by Decreasing GLP-1 Secretion.. <i>Nutrients</i> , 2021 , 14,	6.7	1
62	Semaglutide for the Treatment of Obesity.. <i>Trends in Cardiovascular Medicine</i> , 2021 ,	6.9	3
61	Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 ,	6.7	0
60	Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.. <i>Expert Review of Clinical Pharmacology</i> , 2022 ,	3.8	1
59	The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese patients without Diabetes: A Systematic Review and Meta-Analysis.. <i>Hormone and Metabolic Research</i> , 2022 ,	3.1	2
58	Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022 ,	2.2	1
57	Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide. <i>Frontiers in Endocrinology</i> , 2022 , 13,	5.7	1
56	Regulation of Body Weight: Lessons Learned from Bariatric Surgery. <i>Molecular Metabolism</i> , 2022 , 101518.8	18.8	1
55	Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. <i>Pharmaceutical Research</i> ,	4.5	0
54	Pharmacological Approaches in Obesity Treatment. <i>Osmangaz Journal of Medicine</i> ,	0.1	

53	Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. <i>Therapeutic Advances in Chronic Disease</i> , 2022 , 13, 204062232211080	4.9	1
52	Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities. <i>Pharmaceutics</i> , 2022 , 14, 1445	6.4	1
51	A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> ,	10.5	0
50	Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes. <i>Acta Diabetologica</i> ,	3.9	0
49	Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. <i>Molecular Metabolism</i> , 2022 , 101533	8.8	1
48	Adipose tissue, systematic inflammation, and neurodegenerative diseases. <i>Neural Regeneration Research</i> , 2023 , 18, 38	4.5	0
47	Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease.		1
46	Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents.		0
45	Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment. 2022 , 13,		2
44	Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review. Volume 14, 61-67		0
43	Insight into the mechanism of action of anti-diabetic drugs. 2023 , 95-122		0
42	A new era in gut hormone-based pharmacotherapy for people with obesity. 1-10		0
41	Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. 2022 , 10, 2274		2
40	Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. 13,		0
39	The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study. 2022 , 9, 47		0
38	Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity. 2022 , 257, 113967		0
37	Semaglutide for the treatment of overweight and obesity: A review.		1
36	Medical and surgical treatment of postbariatric hypoglycemia: retrospective data from daily practice.		0

35	Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence. 2022 , 27, 107424842211463	1
34	Obesity pharmacotherapy: incretin action in the central nervous system. 2023 , 44, 50-63	0
33	Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs). 2022 ,	0
32	Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: an Australian perspective on guidelines and the global evidence.	0
31	A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese non-human primate model.	0
30	Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: a post hoc analysis.	0
29	Effects of once-weekly semaglutide in obese/overweight patients: A systematic review and meta-analysis.	0
28	Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. 2023 , 24, 158	0
27	Semaglutide delays 4-hour gastric emptying in women with PCOS and obesity.	1
26	Yellow Pea Pasta Enhances the Saltiness and Suppression of Postprandial Blood Glucose Elevation. 2023 , 15, 283	0
25	A Critical Update on the Leptin-Melanocortin System.	0
24	GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. 2023 , 24, 1703	0
23	Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. 2022 , 28, 740-752	2
22	New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. 2023 , 74, 125-139	0
21	Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.	0
20	Sustained Delivery of GLP-1 Receptor Agonists from Injectable Biomimetic Hydrogels Improves Treatment of Diabetes.	0
19	Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program. 2022 , 134, 28-36	0
18	Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice. 14,	0

- 17 Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies. **2023**, 143, 155550 ○
- 16 Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. **2023**, 87, 111091 ○
- 15 Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome. **2023**, 161, 114561 ○
- 14 Efficacy and safety of semaglutide for weight management: evidence from the STEP program. **2022**, 134, 5-17 ○
- 13 Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg. **2022**, 134, 1-4 ○
- 12 Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study). ○
- 11 The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes. **2023**, 35, 253-273 ○
- 10 Hormonal GutBrain Signaling for the Treatment of Obesity. **2023**, 24, 3384 ○
- 9 Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. **2023**, 5, 248-264 ○
- 8 Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single-blind placebo-controlled study. ○
- 7 Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. ○
- 6 The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials. Volume 16, 575-595 ○
- 5 Research progress of gut microbiota and obesity caused by high-fat diet. 13, ○
- 4 The potential role of GLP-1 receptor agonist targeting in fertility-sparing treatment in obese patients with endometrial malignant pathology: a call for research. **2023**, 23, 385-395 ○
- 3 Implicit Measures of Food Wanting **2023**, 173-194 ○
- 2 Potential contributors to variation in weight-loss response to liraglutide. ○
- 1 GLP-1 analogs and regional adiposity: A systematic review and meta-analysis. ○